Bogart Wealth LLC’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bogart Wealth LLC’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25	Closed	–	–	1083
2022 Q3	$0	Buy	+25	New	+$510	﹤0.01%	1016

Other funds holding CRNX

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bogart Wealth LLC's CRNX Position: Q4 2022 in Review

Bogart Wealth LLC sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2022, closing a stake of 25 shares.

Bogart Wealth LLC first reported a position in CRNX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 122 funds tracked by Wall St. Rank hold CRNX as of Q4 2022.

Bogart Wealth LLC reported no remaining Crinetics Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Bogart Wealth LLC sold 25 Crinetics Pharmaceuticals shares in Q4 2022.
Bogart Wealth LLC first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Bogart Wealth LLC's Crinetics Pharmaceuticals position peaked at $0 in Q3 2022.
122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2022.

Based on Bogart Wealth LLC's 13F filing for Q4 2022, filed 6 Feb 2023.